Shionogi announced that its Board of Directors, at a meeting held on 22 December, 2025, resolved to acquire a newly established company that Tanabe Pharma Corporation will create to hold the rights to RADICAVA ORS (edaravone) and IV RADICAVA.

Tanabe Pharma plans to form this new entity and Shionogi intends to purchase 100 percent of its shares. As part of the transaction, a new business company established by Tanabe for RADICAVA in the US will become a wholly owned subsidiary of Shionogi Inc.

“We are pleased to welcome RADICAVA to Shionogi. This critically important medicine was created to reduce the devastating burden of ALS, and we are honoured to assume responsibility for it and to sustain and grow the relationships Tanabe Pharma has established with the patient and healthcare communities in the US,” said Isao Teshirogi, PhD, CEO, Shionogi.

RADICAVA ORS is approved by the US Food and Drug Administration (FDA) and other regulatory agencies around the world for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease for which there is no cure and few treatment options. RADICAVA ORS, along with a previously available intravenous formulation, have been used to treat more than 20,000 people with ALS in the US to date.

“We are very excited to welcome this team and outstanding medicine to our US business. This planned acquisition will solidify our strategic focus in rare disease and immediately add capabilities to ensure long-term success in this important category. Going forward, this infrastructure will support future launches in rare disease including Shionogi’s development programmes in Fragile X syndrome, Jordan’s Syndrome and Pompe disease,” said Nathan McCutcheon, President and CEO, Shionogi Inc.